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Abstract
Genetic testing for BRCA1 and BRCA2 (BRCA1/2) mutations can
provide important information for women who are concerned about
their breast and ovarian cancer risks and need to make relevant
prevention and medical management decisions. However, lifetime
risks of breast cancer in individual BRCA1/2 mutation carriers have
been confusing to apply in clinical decision-making. Published risk
estimates vary significantly and are very dependent on the
characteristics of the population under study. Recently, Begg and
colleagues estimated cancer risks in a population-based study of
BRCA1/2 mutation carriers. Here, we discuss the clinical decision-
making implications of this research in the context of risk factors
that may influence risk estimates in BRCA1/2 mutation carriers.
Variation in breast cancer risk in BRCA1 and
BRCA2 mutation carriers
In 1995, Easton and colleagues [1] provided an estimate of
greater than 80% for the lifetime risk of breast cancer in
BRCA1 carriers. This estimate, the highest reported, was based
on families with at least four individuals with breast and/or
ovarian cancer collected for linkage analysis to identify genes
associated with familial breast cancer. In contrast, studies of
unselected breast cancer patients have estimated risks in the
40% to 60% range, while studies examining risk estimates in
families attending high-risk clinics have intermediate risk
estimates of 60% to 80% [2-5]. These wide-ranging risk
estimates, as well as studies that suggest wide interindividual
variability in risk even within families with the same BRCA1/2
mutation, suggest that there is no ‘correct’ risk estimate that can
be applied to all women, and there are risk modifiers in
BRCA1/2 mutation carriers. These modifiers are likely to include
reproductive and environmental exposures, genes at other loci,
and the nature of an individual’s family history.
Family history matters
In families with BRCA1/2 mutations, relatives of probands
with ovarian cancer have a higher risk of ovarian cancer, and
relatives of probands with breast cancer have a higher risk of
breast cancer. For example, Lee and colleagues [6] examined
the lifetime risk of cancer in first-degree relatives (FDRs) of
BRCA1/2 mutation carriers with breast or ovarian cancers.
The standardized incidence ratio for breast cancer was 10.6
(95% confidence interval 5.2 to 21.6) in FDRs of breast
cancer probands and 3.3 (1.4 to 7.5) in FDRs of ovarian
cancer probands (p = 0.02). Similarly, the standardized inci-
dence ratio for ovarian cancer was 7.9 (1.2 to 5.3) for FDRs
of breast cancer probands, and 11.3 (3.6 to 31.9) for FDRs
of ovarian cancer probands, although this difference was not
statistically significant (p = 0.37). Why should this be?
Phenotype-genotype correlations of specific gene mutations
exist that suggest that some mutations are more likely to
confer risk of ovarian cancer versus breast cancer [7,8].
However, it is not likely that such genotype-phenotype
association is sufficient to explain the wide ranges of risks
that have been observed. Thus, exposures or genes at other
loci may also modify risk.
Exposures
Factors including parity, age at menarche and first birth,
duration of breast feeding, mammographic density, exogenous
hormone exposures, and dietary factors, including alcohol
intake, are known to impact breast cancer risk in the general
population (reviewed in [9-13]). These factors may also
cluster in families. The impact of reproductive factors on
breast cancer risk in BRCA1/2 mutation carriers is largely
unresolved, although recent large-scale studies have reported
that exogenous hormone exposures (for example, oral contra-
ceptives) and reproductive history may alter breast cancer
risk [14-17]. Other environmental exposures have been
investigated among BRCA1/2 mutation carriers, including
cigarette smoking and caffeine intake, but results have been
inconsistent [18-21].
Medical interventions, such as risk-reducing salpingo-
oophorectomy (RRSO), have also been demonstrated to
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decrease breast and ovarian cancer risk, but are often not
considered in studies estimating penetrance [22,23]. Since it
has been observed that use of RRSO varies by population
[24], difference in risk estimates may also be affected by
variable use of these preventive options.
Finally, variability in cancer risks have been reported by year
of birth [5], suggesting that changes in reproductive history,
exposures or other risk factors that vary by birth cohort may
influence cancer risks [5]. While it is not clear whether these
effects are due to true cancer risk modification rather than
selection biases, birth cohort effects could have influenced
cancer risks and risks in different reports.
Modifier genes
There is increasing evidence that genetic modifiers of
BRCA1/2 risk exist. The most clear-cut is modification of
BRCA2-associated breast cancer risk by RAD51 [25], but
other genes, including FGFR2,  TNRC9,  AURKA, and
MAP3K1 [26-28], have been suggested as risk modifiers.
Although their effects are quite modest, interactions of
genotypes with exposures, birth cohort effects, reproductive
factors, and interventions such as RRSO may provide
significant information about risk.
The Begg study
Begg and colleagues [29] examined cancer risks using 2,098
women diagnosed with breast cancer between 1985 and
2000 (1,394 with unilateral breast cancer, 704 with bilateral
breast cancer) who participated in the Women’s Environ-
mental Cancer and Radiation Epidemiology (WECARE)
study. A total of 109 BRCA1 and 72 BRCA2 mutation
carriers were identified. Cancer risks were estimated for
FDRs of these women. The study found risk estimates signifi-
cantly lower than in studies of high-risk families [1], with a
cumulative risk of breast cancer to age 70 of 36% to 48% for
BRCA1 carriers, and 47% to 59% for BRCA2 carriers.
Increased risk was associated with a younger age of the
proband, and a trend toward increased risk was seen for
relatives of probands with bilateral versus unilateral breast
cancer.
Despite the useful information provided by this research,
there are several considerations to be made in interpreting
this study. Despite the large population based sample, only
181 mutation carriers were identified (with 598 FDRs, of
whom 50% were estimated to be mutation carriers), thus
limiting the power to estimate cumulative risks. A very large
number of BRCA1/2 mutation carriers, 58%, had no FDR
affected with breast cancer; however, several reasons based
on the design of the study may account for this. First, only
FDRs were examined and thus breast cancer in the paternal
linage was not considered. Information is not given on the
percentage of probands with no sisters or daughters, a fact
particularly relevant in those with a mutation inherited from
the paternal lineage. It is not known if probands or their FDRs
were aware of their mutation status and, if so, what pro-
phylactic measures might have been taken, such as mastec-
tomy or oophorectomy. Both of these interventions would
significantly alter cancer risk. Ovarian cancer was not
considered as an endpoint. The study population was
uniquely selected as patients were eligible only if they had
node negative breast cancer diagnosed under the age of 55
between 1985 and 2000, and then were recruited between
2000 and 2004. Therefore, survival and other biases may
exist. Finally, the authors did not consider potential birth
cohort effects, which have been identified in multiple studies
and may have influenced some results.
The major limitation in making clinical inferences from this
study, however, is that the sample studied by Begg and
colleagues may not represent the women who currently
undergo genetic testing. Individuals without a significant
family history are not recommended to have genetic testing
[30] and this population will not have routine insurance
coverage for genetic testing. Thus, the clinical implications of
Begg and colleagues (and other studies of this type) are
limited by sampling/design issues.
What do we need to know before changing
clinical recommendations?
Individualized risk assessment is the holy grail of the human
genome - not only for BRCA1/2 mutation carriers but for the
general population. Such assessment may be possible:
proband cancer type matters, evidence for genotype-
phenotype correlations exist; there is evidence for modifier
genes. However, the most important question is whether
decision-making will change when this information is available.
Will we ever feel comfortable telling a mutation carrier that she
does not need RRSO, particularly if we continue to have no
effective ovarian cancer screening strategy? Will physicians
ever insist on prophylactic mastectomy? Will women make
different decisions based on a 40% lifetime risk of breast
cancer versus a 60% lifetime risk? These and many other
unanswered questions remain even as we strive for improved
risk estimation and stratification.
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